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Abstract: The term orthodisease defines human disorders in which the pathogenic gene has orthologs
in model organism genomes. Yeasts have been instrumental for gaining insights into the molecular
basis of many human disorders, particularly those resulting from impaired cellular metabolism.
We and others have used yeasts as a model system to study the molecular basis of Hailey-Hailey
disease (HHD), a human blistering skin disorder caused by haploinsufficiency of the gene ATP2C1
the orthologous of the yeast gene PMR1. We observed that K. lactis cells defective for PMR1 gene
share several biological similarities with HHD derived keratinocytes. Based on the conservation
of ATP2C1/PMR1 function from yeast to human, here we used a yeast-based assay to screen
for molecules able to influence the pleiotropy associated with PMR1 deletion. We identified six
compounds, Kaempferol, Indirubin, Lappaconite, Cyclocytidine, Azomycin and Nalidixic Acid
that induced different major shape phenotypes in K. lactis. These include mitochondrial and the
cell-wall morphology-related phenotypes. Interestingly, a secondary assay in mammalian cells
confirmed activity for Kaempferol. Indeed, this compound was also active on human keratinocytes
depleted of ATP2C1 function by siRNA-treatment used as an in-vitro model of HHD. We found that
Kaempferol was a potent NRF2 regulator, strongly inducing its expression and its downstream target
NQO1. In addition, Kaempferol could decrease oxidative stress of ATP2C1 defective keratinocytes,
characterized by reduced NRF2-expression. Our results indicated that the activation of these
pathways might provide protection to the HHD-skin cells. As oxidative stress plays pivotal roles in
promoting the skin lesions of Hailey-Hailey, the NRF2 pathway could be a viable therapeutic target
for HHD.
Keywords: Hailey-Hailey; NRF2; NOTCH1; oxidative-stress
1. Introduction
Hailey-Hailey disease (HHD), also called benign familial pemphigus, is an autosomal dominant
blistering skin disorder, manifesting in the 3rd to 4th decades of life. The overall incidence and
prevalence of HHD is unknown, although some authors have reported an incidence between 1:40,000
and 1:50,000 [1,2]. The genetics and pathophysiology of this skin disorder have been linked to
mutations in the ATP2C1 gene [3,4]. The gene, located on the long arm of chromosome 3, 3q21-q24
region, encodes the human secretory pathway Ca2+/Mn2+ ATPase, hSPCA1 [5]. Although ATP2C1
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is mostly localized to the Golgi apparatus, it regulates also endoplasmic reticulum (ER) Ca2+ stores
with effects on both Golgi and ER functions. The lack of ATP2C1 in keratinocytes leads to the loss of
cell-to-cell adhesion (acantholysis) among the cells of the suprabasal layer of epidermis probably due
to a retraction of keratin intermediate filaments from the desmosomal plaques [6]. Although ATP2C1
mutations are 100% penetrant, currently there is no treatment known to be effective in reducing
the cutaneous manifestations of HHD. The Standard of Care (SOC) treatment consists in either
topical or oral administration of corticosteroids often used in combination with topical/systemic
antimicrobial agents. However, prolonged treatment course of steroids is limited due to their side
effects, most commonly skin atrophy. This last aspect must be carefully considered, because in
HHD-patients, lesion development is associated with the simple friction of the skin, and we found
that HHD-keratinocytes are characterized by wound defects [7]. Additionally, patients develop
lesions refractory to corticosteroids. As lesions became recalcitrant to SOC treatment, several possible
treatments have been proposed, including: Botulinum toxin injection and photodynamic therapy [8].
However, evidence for the above indicated treatments of HHD is limited to case reports, case series,
and expert opinion. The development of causal treatment strategies (i.e., molecular therapy-based) is
highly desirable and could be reached through intensified efforts to elucidate the various molecular
mechanisms underlying the disorder. HHD is associated with the loss of a single copy of the ATP2C1
gene. ATP2C1 is likely essential in humans, as more severe phenotypes are found in patients who
suffer clonal loss of both copies of the gene [9]. Consistently, mice embryos homozygous for null
mutations in ATP2C1 die with defects in neural tube closure, while heterozygotes show susceptibility
to squamous cell tumors, a phenotype observed rarely in humans with Hailey-Hailey; [10,11] and
our personal observation); however, this mouse model fails to reproduce the clinical manifestation
of the disease, unfortunately opposing the applicability of this mouse model in HHD. Yeast has
been increasingly used as a model and tool for biomedical research [12,13], based on the observation
that basic cellular functions are conserved from yeast to humans and that disease’s key players are
often evolutionarily conserved. Indeed, about 30% of the genes known to be involved in human
diseases have a yeast ortholog [14,15]. For these reasons, this simple organism is widely used for
high-throughput genetic and small-molecule screens to find possible pharmacological drugs for many
human diseases. This is still true in the study of Hailey-Hailey disease. Indeed, both the budding
yeasts Saccharomyces cerevisiae (S. cerevisiae) and Kluyveromyces lactis (K. lactis) express the orthologous
gene of ATP2C1, PMR1 (plasma membrane ATPase related) [16–18]. Yeast cells deprived of PMR1
display pleiotropic phenotypes; some of them have been reported also for HHD keratinocytes,
including alterations in Ca2+ homeostasis, mitochondrial dysfunctions and an increased production of
reactive oxygen species (ROS) [3,19,20]. Oxidative stress represents a hallmark of the keratinocytes
derived from the lesions of HHD patients and it could be associated to the decreased action of
some detoxifying systems. Particularly, we previously demonstrated that one of the detoxifying
enzymes involved in the pathophysiology of HHD is the Glutathione S- transferase (GST) [21].
Indeed, performing a genetic screening, we found that the expression of mammalian GST in
the yeast K. lactis lacking PMR1 recovers the oxidative alterations of mutant cells, promoting a
reduction to the sensitivity to ROS generating compound (H2O2), decreasing its cellular content
and restoring the mitochondrial function. Additionally, we showed that, both in yeast cells and
in the lesional-derived keratinocytes of HHD patients, the expression of this detoxifying gene is
down-regulated [21]. Based on these observations, in this study we establish a yeast-based screening
assay, designed to identify drugs that could be active against Hailey-Hailey disorder. Natural product
collections are bioactive and structurally diverse molecules. It has been estimated that 60% of current
FDA-approved drugs have origins in natural products, illustrating the power of these compounds in
drug discovery [22]. Thus, we took advantage of a library of 131 natural compounds to analyze their
ability to suppress the phenotypes of K. lactis pmr1∆ cells. Due to the great relevance of the oxidative
stress in HHD-derived keratinocytes, in the initial screening system we evaluated if the drugs were
able to recover the oxidative-stress alterations of our mutant. With this aim, we analyzed the growth
Int. J. Mol. Sci. 2018, 19, 1814 3 of 15
in the presence of H2O2 or menadione, two generators of ROS at extracellular and mitochondrial
level, respectively. From the first screening, we selected six compounds that were utilized for further
analysis. Specifically, we analyzed if the six positive hits were able to alleviate other main defects
of pmr1∆ cells, like the calcium homeostasis alteration, the cell wall defects and the mitochondrial
dysfunction. Moreover, we showed that one of the identified hit in the yeast screening was effective
also in cellular culture of keratinocytes silenced for ATP2C1. These results validate our approach that
provides the use of the yeast K. lactis to screen drugs with potential to treat the HHD disease.
2. Results
2.1. Primary Screen of Chemical Libraries Using KLPMR1-Based Assay
Previously, we demonstrated the feasibility of using the yeast Kluyveromyces lactis for modeling
Hailey-Hailey disease [21]. In the present study we performed a pharmacological screening using a
library of 131 natural molecules to analyze their ability to suppress the pmr1∆ phenotypes (Figure 1A).
The drug collection includes inhibitors, activators and antagonists acting on molecular targets involved
in different signaling pathways. Since the lack of the Golgi Ca2+-ATPase in yeast, as well as in human
HHD keratinocytes, induced a prominent increase of ROS production [20,23], we started our screening
testing with the natural molecules capability to ameliorate the growth properties of the pmr1∆ strain
under oxidative-stress conditions. Toward this aim, ROS conditions were achieved either exogenously
by H2O2 administration or endogenously by menadione treatment (Figure 1B). First, we tested all the
molecules at a concentration of 200 M. The compounds that had partial or no effects were tested at
a concentration of 250 M. Furthermore, the molecules found to be toxic at 200 M were analyzed at a
lower concentration (100, 10 and 5 M) and those compounds showing either toxicity or ineffectiveness
at a lower concentration were excluded from further analysis (Table S1). As shown in Figure 1B,
six compounds were able to reduce the sensitivity of klpmr1∆ mutant to menadione and/or H2O2.
The molecules S2328, S2386, S2314 and, more effectively, the S2387 and S2267 decreased the growth
defects of mutant cells in the presence of menadione. Meanwhile, S1973 and S2314 were more effective
against H2O2 (Figure 1B). This indicates that the action of the different compounds depends on the
localization of the ROS source. These six molecules, selected from the preliminary screen, belong
to different class of drugs. Indeed, the S2386 and S1973 (Indirubin and Cyclocytidine) are used in
medicine as chemotherapeutics [24,25], S2387 and S2314 (Lappaconite Hydrobromide and Kaempferol)
have an anti-inflammatory action [26], and S2328 and S2267 (Nalidixic acid and Azomycin) are
mainly recognized as anti-bacterial drugs [27]. A dose–response curve was then performed for the six
compounds (Figure S1) and the EC50 was determined as reported in Table 1.
Table 1. Median effective concentration (EC50) of the compounds selected in the yeast primary screening.
Chemicals Oxidative Stress Selection EC50 (mM)
S1973 (Cyclocytidine) H2O2 51.26 ± 1.19
S2267 (Azomycin) Menadione 102.64 ± 0.50
S2314 (Kaempferol) H2O2 50.5 ± 0.44
S2328 (Nalidixic acid) Menadione 50.13 ± 4.84
S2386 (Indirubin) Menadione 48.56 ± 3.01
S2387 (Lappaconite) Menadione 9.35 ± 0.42
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Figure 2. Analysis of calcium alteration. WT and Klpmr1∆ cells exposed or not to the individual 
natural molecules, were grown for 24 h in Yeast Extract-Peptone-Dextrose (YPD) medium at 30 °C. 
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2.3. Cell Wall Phenotype 
K. lactis strain deleted for PMR1 gene had defects in the cell wall organization. Indeed, as shown 
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we previously reported that in wild type cells the chitin is mainly deposited to the bud-emergence 
sites, whereas in the Klpmr1∆ strain the fluorescence is distributed across the entire cell wall [17]. To 
analyze the effect of the selected hits on the cell wall structure of our mutant, the CFW staining was 
performed. We found that all the six molecules were able to recover the wild type-like chitin 
distribution (Figure 3). However, the molecules S1973 and S2314 induced a recovery of 40%; 
meanwhile, the compounds S2267, S2387 and S2386 relieved the wall disorganization in about 50% 
of the cells. Particularly, the compound S2328 strongly recovered the cell wall morphology in 80% of 
klpmr1∆ cells. 
 
Figure 3. Chitin distribution of mutant cells treated with the six selected products. PMR1-deleted 
cells, grown with or without the individual compounds for 24 h at 30 °C, were stained with the 
chitin-binding dye CFW. At least 500 cells were analyzed for each treatment to determine the 
percentage of cell wall recovery. Wild type cells (WT) represent the positive control. Scale bar 2 µm.  
Figure 2. Analysis of calcium alteration. WT and Klpmr1∆ cells exposed or not to the individual
natural molecules, were grown for 24 h in Yeast Extract-Peptone-Dextrose (YPD) medium at 30 ◦C.
Then, serial dilutions of the cultures were spotted onto solid medium supplemented or not with 20
mM EGTA. Scale bar:
2.3. Cell Wall Phenotype
K. lactis strain delet d for PMR1 gene had defects in the cell wall organization. Ind ed, as shown
by using the fluorescent dye Calcofluor white (CFW), which binds the cell wall component chitin,
we previously reported that in wild type cells the chitin is mainly deposited to the bud-emergence sites,
whereas in the Klpmr1∆ strain the fluorescence is distributed across the entire cell wall [17]. To analyze
the effect of the selected hits on the cell wall structure of our mutant, the CFW staining was performed.
We found that all the six molecules were able to recover the wild type-like chitin distribution (Figure 3).
However, the molecules S1973 and S2314 induced a recovery of 40%; meanwhile, the compounds S2267,
S2387 and S2386 relieved the wall disorganization in about 50% of the cells. Particularly, the compound
S2328 strongly recovered the cell wall morphology in 80% of klpmr1∆ cells.
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Figure 3. Chitin distribution of mutant cells treated with the six selected products. P R1-deleted cells,
grown with or without the individual compounds for 24 h at 30 ◦C, were stained with the chitin-binding
dye CFW. At least 500 cells were analyzed for each treatment to determine the percentage of cell wall
recovery. Wild type cells (WT) represent the positive control. Scale bar 2 µm.
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2.4. Mitochondrial Morphology
Mitochondria are responsible for the main source of ROS in most cells, linking mitochondrial
respiration with ROS effects on cellular function [28]. Wild type cells show a tubular network of
mitochondria as long as in the Klpmr1∆ strain these organelles appear as dots, indicating an alteration in
their functionality [20]. Thus, we addressed the capability of the selected hits to rescue the mitochondria
alteration of Klpmr1∆ cells. With this aim, we incubated our sample with the fluorescent probe DASPMI
that is taken up by mitochondria as a function of membrane electrochemical potential. As shown
in Figure 4, we found that three drugs (S2386, S2314 and S2387) restored the wild type-like tubular
network of mitochondria. The drug S2314 totally relieved the mitochondria defects of our mutant
while the molecules S2386 and S2387 worked in the 60% of Klpmr1∆ cells. Overall, our data indicate
that each molecule acts on specific phenotypes of Klpmr1∆ cells (Table S2). This is in agreement with
the fact that the selected molecules belong to different classes of drugs.
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Figure 4. Effect of the natural compounds on the altered mitochondrial function of pmr1∆ cells.
The mutant cells, untreated or treated with the indicated molecules for 24 h, were stained with the vital
dye DASPMI and immediately the fluorescence micrographs were taken. To calculate the percentage of
cells with altered tubular mitochondria morphology, at least 500 cells were analyzed for each condition.
Wild type strain (WT) was used as a control. Scale bar 2 µm.
2.5. Drugs Active in the Yeast-Based Assay Were Also Active in Human Cells
We next teste the compounds that were active in our yeast-based assay in a human
cell-based model of HHD-disease; in particular, we used a iRNA-ATP2C1 to mimic ATP2C1-loss of
function [7,23,29]. We previously found that siATP2C1-treated cells share most of the defects observed
in K. lactis cells defective for PMR1 gene including oxidative stress [7,21,23,29,30]. We established
that ATP2C1 inhibition in both immortalized and primary keratinocyte cells results in an impaired
proliferation; thus, the compounds from the yeast screening were tested in human keratinocytes
and we sought to perform our primary screen in HaCaT cells determining how the morphology/cell
proliferation defects of si-ATP2C1 cells were influenced by the treatment with the identified compounds.
HaCaT cells were transf cted with ither siATP2C1 or -siCTR after 24 h treated with th indicated
compound for further 24 h. Int restingly, we observ d that Kaempferol (EC50 0.8 µM) treatment
rescued the berrant cell morphology and cell growth ability of siATP2C1-treated c lls (Figure 5).
In a second step, we validated the Kaempferol effect by performing a secondary analysis in human
primary keratinocytes. Similarly, to our observation in HaCaT cells, we observed that Kaempferol
treatment was able to rescue the aberrant cell morphology/growth of siATP2C1 treated human primary
keratinocytes (Figure 6).
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siRNA-ATP2C1; 24 h post-transfection, cells were treated with the indicated compounds at 10 µM for a
further 24 h and analyzed by microscopy. (100×magnification). The potencies (EC50 = 0.8 µM +/− 0.1)
of Kaempferol were obtained from the dose–response curves using GraphPad Prism (GraphPad
Software, La Jolla, CA, USA). Scale bar: 50 µm.
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2.6. Potential Mechanism of Kaempferol against ATP2C1-Induced Oxidative-Stress through Regulation of
Nuclear Factor Erythroid-2-Related Factor 2 Signaling
HHD lesion-derived keratinocytes are characterized by increased oxidative stress and decreased
expression levels of both NOTCH1 and NRF2 [7]. We have established that altered function of
these factors plays an important role in the alteration observed in HHD-derived keratinocytes [7].
Both NOTCH1 and NRF2 factors are important determinant of skin homeostasis and we found
that they are differentially regulated between normal and HHD-derived keratinocytes, as well as
in HaCaT cells interfered for ATP2C1 function [7]. Thus, we tested the expression of these two
factors in response to Kaempferol treatment. Both HaCaT cells and primary human keratinocytes
were transfected with either siATP2C1 or -siCTR, and 24 h post-transfection, they were treated with
Kaempferol for a further 24 h. In both cell types NOTCH1 expression wasn’t affect by Kaempferol
treatment, while NRF2 expression was strongly increased. This observation indicates that loss of
NRF2 activity in defective ATP2C1-cells might have a direct effect on increased oxidative-stress
(Figure 7). Thus, the antioxidant property of Kaempferol and its ability to restore NRF2 expression
might play a role in reducing the oxidative-stress of siATP2C1-treated cells. Interestingly, Kaempferol
did not significantly affect the steady-state level of NRF2 mRNA, indicating that it stimulates
NRF2 expression by protein stabilization (Figure 7). NRF2 activation directly regulates antioxidant
gene transcription [31,32]. NRF2 activation can be modulated by flavonoid as Kaempferol [31,32];
thus, the reduced expression NRF2 in lesioned HHD skin may play a role in the transcriptional
down-regulation of antioxidant genes [7,21,30]. Therefore, we first tested if Kaempferol treatment
affects the level of oxidative-stress present in siATP2C1-treated cells (Figure 7F). The percentage of
DFCA-positive cells in siATP2C1 cells reached 40–60% at 48 h after transfection, whereas only 15% of
the siRNA-CTR control cells were DFCA-positive (data not shown and [7]). Interestingly, treatment
with Kaempeferol reduced the oxidative stress of both siCTR and of siATP2C1-treated keratinocytes.
However, the extent of oxidative-stress in siATP2C1 still remained higher than siCTR cells, indicating
that the causative factors and underlying mechanism of oxidative stress still remain active (Figure 7F).
NRF2 directly affects the homeostasis of ROS by regulating the expression of several antioxidant
genes. Therefore, we analyzed the expression of NRF2-target genes in siATP2C1 and si-CTR-interfered
primary keratinocytes after Kaempferol treatment. In ATP2C1 defective cells we observed the loss
of NRF2 protein expression; however, only two down-regulated genes (NQO1 and GST-M1) were
similarly altered by siRNA-ATP2C1 treatment (Figure 8). Kaempferol treatment partially suppressed
oxidative stress in ATP2C1-defective cells and this was paralleled by increased levels of NRF2 and
NQO1/GST-M1 expression. Our data indicate that Kaempferol treatment rescues the impaired NRF2
expression of ATP2C1 defective cells and, in turn, NQO1/GST-M1 expression (Figure 8).
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Figure 7. Cell extracts were prepared from both NHKCs (A,B) and HaCaT cells (C,D) transfected
with either control (siRNA-CTR) or ATP2C1-specific siRNA oligonucleotides; 24 h later, cells were
treated with Kaempferol (10 µM) for 24 h and the cell extracts analyzed by western blot; (E) Cells were
treated as in C, and expression of NRF2 was determined by RT-PCR; (F) Keratinocytes-derived cell line,
HaCaT, was transfected with either siRNA-CTR or siRNA-ATP2C1 and cells w re analyzed by flow
cytometry. The percentage of ROS-positive cells is also shown. The absolute value of ROS of both from
siRNA-CTR and siRNA-ATP2C1 Kaempferol-untreated cells was arbitrary indicated as 100%.
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Figure 8. (A–C) NHKC cells were transfected wit co trol (siRNA-CTR) or ATP2C1-specific siRNA
oligonucleotides; 24 h later, cells were treated with Kaempferol (10 µM) for 24 h, the total RNA extracted,
and the expression of the indicated targets analyzed by RT-PCR; (D) ATP production in both yeast (left)
and primary human keratinocytes (right). ATP levels were analyzed in Klpmr1∆ and WT cells, and ATP
production was assessed in primary human keratinocytes transfected with control (siRNA-CTR) or
ATP2C1-specific siRNA oligonucleotides.
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2.7. Increased Mitochondrial Activity as a Source of Oxidative Stress in ATP2C1-Defective Keratinocytes
Reactive oxygen species (ROS) are generated as a by-product of mitochondrial oxidative
phosphorylation. However, inhibition of the mitochondrial electron transport induces generation of
ROS that results in mitochondrial dysfunction [33]. NQO1 influences several aspects of mitochondrial
function including: elevation of mitochondrial complex I activity; increased ATP production;
maintenance of an elevated NAD/NADH ratio; and decreased ROS production ([33] and references
therein). ATP2C1 defective keratinocytes are characterized by reduced NQO1 expression (Figure 8).
Thus, we tested the ATP production in both ATP2C1-defective keratinocytes and Klpmr1∆ cells as a
sign of mitochondrial function; we found that ATP production was decreased in Klpmr1∆ cells in line
with the observed altered mitochondrial shape, indicating that mitochondrial dysfunction results in a
cascade of events that include reduced ATP production (Figure 8D). Unexpectedly, we found that ATP
production was increased in keratinocytes depleted of ATP2C1 function (Figure 8D). This observation
indicates that in ATP2C1-defective mammals, cells with increased oxidative stress may be determined,
at least in part, by increased mitochondrial activity, rather than by its dysfunction.
3. Discussion
Calcium [Ca2+] serves as an ubiquitous second messenger in all eukaryotes [34]. There are several
biological processes regulated by temporally and spatially defined changes of Ca2+ concentration in
the cytoplasm or in defined organelles [34]. ATPase pumps modulate global cytosolic calcium levels
and/or may control only the calcium levels, in particular intracellular calcium stores, e.g., endoplasmic
reticulum, Golgi. In this context, one regulator of Golgi luminal calcium levels is the secretory pathway
calcium ATPase 1 (SPCA1), an active transporter of calcium into the secretory pathway [4,35–38].
Mutations in ATP2C1 (SPCA1) manifest as Hailey-Hailey disease, an autosomal dominant skin
disorder [3]. Hailey-Hailey disease is characterized mainly by skin-specific phenotype symptoms
characterized by the loss of cell-cell adhesion (acantholysis) [3]. Mutations in ATP2C1 result in the
decrease of ATP2C1 protein expression. There have been very few studies addressing the consequences
of ATP2C1 inhibition in mammalian cells. In this context, yeast systems have become an attractive
choice for the study of functionally conserved ATP2C1 function. We have developed a model yeast
system to study the poorly defined genetic functions of the ATP2C1 gene in Hailey-Hailey disease
development. Cellular phenotypes associated with ATP2C1/PMR1 loss of function in yeast can be
investigated to clarify the cellular and molecular functions of ATP2C1 in keratinocytes. In line with
the notion that Ca2+ signal regulates a multitude of downstream responses, we show here that the
strain bearing the KlPMR1 gene disruption exhibited a pleiotropic phenotype. The pleiotropy of the
mutant suggests that Pmr1 steers different calcium-dependent signal pathways to control distinct
physiological processes. Here, we carried out a phenotypic screening to identify compounds able to
revert either single or multiple phenotypes of Klpmr1∆ strain. Thus, understanding the mechanism of
selective rescue by these compounds would shed light on the relevant molecular mechanisms to target
for therapy. In this frame, we performed a pharmacological screening using a library of 131 natural
molecules to analyze their ability to suppress the Klpmr1∆ phenotypes. Since the lack of the Golgi
Ca2+-ATPase in yeast, as well as in human HHD keratinocytes, induced a prominent increase of ROS
production [20,23], we analyzed first the capability of the library to ameliorate the growth properties of
the Klpmr1∆ strain under oxidative stress conditions. ROS conditions were achieved either exogenously
by H2O2 administration or endogenously by menadione treatment. Six compounds, Indirubin (S2386),
Cyclocytidine (S1973), Lappaconite Hydrobromide (S2387), Kaempferol (S2314), Nalidixic acid (S2328)
and Azomycin (S2267) were able to reduce the sensitivity of Klpmr1∆ mutant to menadione and/or
H2O2. The molecules S2328, S2386, S2314 and, more effectively, S2387 and S2267 decreased the growth
defects of mutant cells in the presence of menadione. Meanwhile, S1973 and S2314 were more effective
against H2O2. This indicates that the action of the different compounds depends on the localization of
the ROS source. Then, we addressed if the six compounds selected in our screening were also able to
rescue the multiple phenotypes associated with the deletion of the PMR1 gene. Our findings indicated
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that selected drugs were able to target the phenotypic traits of Klpmr1∆ mutant in both a multiple and
phenotype-specific manner. Indeed, we found that Indirubin and Cyclocytidine, but not the other
selected compounds, were able to revert the defect of Klpmr1∆ in regulation of intracellular calcium
homeostasis as displayed by alterations in the sensitivity to Ca2+ chelator EGTA. Conversely, all six
molecules were able to recover the defective wall structure of the mutant. However, we found that
different molecules exhibited different strengths of suppression, with Nalidixic acid recovering cell
wall morphology in 80% of klpmr1∆ cells. Similarly, we found that of the six selected compounds,
three drugs (S2386, S2314 and S2387) restored the wild type-like tubular network of mitochondria.
Among these compounds, only S2314 fully rescued the mitochondrial defects. The observation that
compounds suppress different sets of phenotypes and at different strengths may suggest that Pmr1 loss
of function elicits distinct and separable downstream responses. We have proven that yeast represents
a useful model organism for investigating molecular and cellular aspects of Hailey-Hailey diseases,
which may help to develop precise therapies for this disorder. Here we found six compounds able to
ameliorate the multiple phenotypes of klpmr1∆ cells, summarized in the Supplementary Table S2.
Among the selected molecules, we found that Kaempferol was particularly effective for reverting
the oxidative alterations of mutant cells, alleviating the sensitivity to ROS-generating compounds
(H2O2 and menadione), decreasing the ROS cellular content, and restoring the mitochondrial function.
Interestingly, we observed that Kaempferol treatment rescued the aberrant cell morphology and cell
growth ability of siATP2C1-treated keratinocyte cells (Figures 5 and 6). Moreover, NRF2 expression
was increased by Kaempferol treatment, further supporting our observation that loss of NRF2
activity in defective ATP2C1 cells may have a direct effect on increased oxidative stress. Interestingly,
treatment with Kaempferol reduced the oxidative stress of siATP2C1-treated keratinocytes. Moreover,
Kaempferol treatment induced an increase of NRF2 expression, as well as a reduction of oxidative
stress, in si-ATP2C1-treated keratinocytes. These data further support our observation that loss of
NRF2 activity in defective ATP2C1 cells may have a direct effect on increased oxidative stress. ROS
are generated as a by-product of mitochondrial oxidative phosphorylation. Here we found that
mitochondrial integrity is altered by inactivation of the K. lactis PMR1 gene, and Kaempferol treatment
led to the rescue of mitochondrial phenotype together with decreased sensitivity to ROS sources.
Thus, we tested the mitochondrial functionality of both klpmr1∆ cells and siATP2C1-interfered human
keratinocytes by analyzing ATP production. In line with the altered mitochondrial morphology, ATP
production was decreased in Klpmr1∆ cells (Figure 8D). Unexpectedly, we found that ATP production
was increased in keratinocytes depleted of ATP2C1. Stimulation of mitochondrial oxidative metabolism
by Ca2+ is now generally recognized as an important mechanism for the control of cellular ATP
homeostasis. Increases in cytosolic calcium results in an increased mitochondrial Ca2+ uptake and ATP
synthesis [33]. Thus, it may be possible that in ATP2C1-defective mammals, the increased oxidative
stress of cells is determined by increased mitochondrial activity, rather than by its dysfunction.
4. Materials and Methods
4.1. Yeast Strains, Growth Conditions
The strains used in this study were MW278-20C (MAT a, ade2, leu2, uraA) and CPK1 (MAT a,
ade2, leu2, uraA, PMR1::KanR). The yeast growth media used for all the experiments was YPD medium
(1% yeast extract, 1% peptone, 2% glucose, DIFCO (Difco, Becton Dickinson, Sparks, MD, USA)).
4.2. Library Screen
For the screening, a library of 131 natural products was purchased from Selleck Chemicals
(Houston, TX, USA). The complete list of chemicals screened is provided in Supplementary Table S1.
Compounds were stored as 10 mM stock solutions in dimethyl sulfoxide (DMSO) at −20 ◦C until
use. Compound stocks were diluted in a volume of 1 mL of YPD to the indicated concentrations.
After 24 h of growth at 28 ◦C, five-fold serial dilution of cultures were spotted onto YPD agar plates
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supplemented or not with 60 µM menadione or 4 M H2O2 or 20 mM EGTA, as indicated. The plates
were incubated at 30 ◦C for 3 days. To determine a dose–response curve, mutant cells were treated at
30 ◦C for 24 h with increasing concentrations of each chemical diluted in 1 mL of YPD at the indicated
concentrations. After that, cells were diluted to 0.07 OD600 in 2 mL of YPD containing 3 mM H2O2 or
20 µM menadione. After 24 h of growth at 30 ◦C the optical density (OD) was measured. The EC50
of the compounds was obtained from the dose–response curves using GraphPad Prism (GraphPad
Software, La Jolla, CA, USA).
4.3. Fluorescence Microscopy
After 24 h of treatment with the molecules, the yeast cells grown in YPD
medium were harvested, washed with water and then mixed 1:1 with the vital dye
2-(4-dimethylaminostyryl)-N-methylpyridinium iodide (DASPMI) as described in [39]. The chitin
staining was performed using the probe Calcofluor White (CFW) by the method of [17]. Epifluorescence
microscopy was carried out with a Zeiss AxioVert 25 microscope fitted with a ×100 immersion
objective and a standard filter set.
4.4. Primary Human Keratinocytes
Primary human keratinocytes were purchased from (Thermo Fisher Scientific, Waltham, MA,
USA). Cells were maintained in modified low calcium medium (EpiLife, Thermo Fisher, Waltham, MA,
USA). Cells at passages 1 and 2 were used for study purposes.
4.5. Cell Culture and Transfection
Primary human keratinocytes and HaCaT cells (70–80% confluent) were maintained in
modified low-calcium medium and transfected using the Lipofectamine -RNAiMAX transfection
Reagent according to manufacturer’s instructions (Thermo Fisher Scientific, Waltham, MA, USA).
Primary keratinocytes were transfected with 100 nmol·L−1 small interfering RNAs (siRNAs) for
validated human ATP2C1 (L-006119-00; Thermo Scientific/Dharmacon, Lafayette, CO, USA) and the
corresponding control scrambled siRNAs cells were analyzed at the indicated times after transfection
by either CMH2DCFDA analysis for ROS detection or Western blot as indicated [23].
4.6. Reagents and Immunoblotting
ATP2C1 antibodies were purchased from Abcam (Cambridge, MA, USA) and NOTCH1 (N1Val)
and NRF2 were purchased from Cell Signaling Technology (Beverly, MA, USA). All cell extracts were
prepared according to the manufacturer’s instructions for detection of phosphor-ERK (Cell Signaling
Technology, Beverly, MA, USA) as previously described [30]. Adenosine triphosphate (ATP) content
of keratinocytes was determined using the luciferin reaction, ATP Determination Kit (Thermo Fisher
Scientific, Waltham, MA, USA). A standard curve was made by using solutions containing increasing
concentrations of ATP.
4.7. RNA Analysis and Reverse Transcriptase-Polymerase Chain Reaction
Total RNA was isolated from cells in guanidine isothiocyanate (Trizol reagent, Thermo Fisher
Scientific, Waltham, MA, USA) and further processed by reverse transcriptase polymerase chain
reaction (RT-PCR) as described in [40]. Each sample was analyzed in triplicate by qRT-PCR and in at
least three independent experiments. qRT-PCR was performed at the opportune annealing temperature
with the primers indicated in Table 2 with SensiFAST SyBr Hi-ROX kit (Bioline, London, UK) or with
specific TaqMan MGB primers/probe using Taqman gene expression assay (Thermo Fisher Scientific,
Waltham, MA, USA)
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Table 2. qRT-PCR primers.











In this work we have explored the use of the yeast K. lactis as a tool to identify specific compounds
that target specific cellular phenotypes and obtain more insight into mechanisms of disease pathology
by probing the mechanisms involved in their action. Oxidative stress represents a hallmark of both
Kluyveromyces lactis lacking PMR1 and keratinocytes derived from the lesional areas of HHD patients
and it could be associated with the decreased action of the transcription factor NRF2, involved in
the regulation of several detoxifying factors. Our results indicated that molecules able to promote
activation of this pathway might provide protection to the HHD-skin cells.
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